TNNT2 and cancer: Cancer patients with non-elevated hs-cTnT (5-year ACM: 44.6%) or NT-proBNP (5-year ACM: 41.4%) showed lower mortality rates than patients with preserved LVEF (5-year ACM: 50.5%) or without a relevant CAD (5-year ACM: 47.8%).